Skip to content

Mitochondrial respiratory chain activity in the brain of young male rats subjected to alloxan-induced diabetes and a ketamine-induced schizophrenia-like model.

Patricia Gomes Wessler, Gustavo Antunes Mastella, Katia Gress, Alexandra S Heylmann, Camila S Amarante, Louyse S Damázio, Eleonor J Soligo Junior, Pauline S Effting, Micaela R Quadra, João Pedro Veronezi Rohling, Emilio L Streck, Alexandra I Zugno

Journal of Psychiatric Research November 11, 2026 DOI: 10.1016/j.jpsychires.2026.11.026 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Experimental animal study (2 × 2 factorial design) Peer reviewed
Sample size 16
Population Male Wistar rats, 23 days old at assignment, divided into four groups (n = 4 per group)
Interventions Alloxan Ketamine
Dose Alloxan 150 mg/kg (single i.p. injection); ketamine 25 mg/kg i.p. daily
Duration Ketamine or saline administered daily from day 4 to day 10
Measures Activities of mitochondrial respiratory chain complexes I, II, II-III and IV
Topics Ketamine Esketamine
Keywords Alloxan Brain energy metabolism Mitochondrial respiratory chain Schizophrenia
Key findings Alloxan-induced diabetes was associated with lower complex II-III activity in the hippocampus and striatum, and an alloxan × ketamine interaction was seen for hippocampal complex I, where alloxan and ketamine each increased activity versus controls but their combination did not. No significant effects were detected in the frontal cortex; the authors characterize the findings as exploratory and requiring replication.

Abstract

Type 1 diabetes mellitus (T1D) and schizophrenia (SZ) have both been associated with impaired brain energy metabolism. We investigated whether alloxan-induced insulin-deficient diabetes modifies the effects of a ketamine-induced schizophrenia-like model on the activity of brain mitochondrial respiratory chain enzymes. Male Wistar rats (23 days old) were assigned to four groups in a 2 × 2 factorial design: Control, Alloxan, Ketamine, and Ketamine + Alloxan. Diabetes was induced by a single intraperitoneal (i.p.) injection of alloxan (150 mg/kg), and ketamine (25 mg/kg, i.p.) or saline was administered daily from day 4 to day 10. The activities of complexes I, II, II-III and IV were measured in tissue homogenates of the frontal cortex, hippocampus and striatum (n = 4 per group) and analyzed by two-way ANOVA, with correction for multiple testing across all outcomes. No observation was excluded from any analysis. Three effects remained significant after correction for multiple testing: alloxan was associated with lower complex II-III activity in the hippocampus (q = 0.016) and striatum (q = 0.016), and an alloxan × ketamine interaction was observed for complex I in the hippocampus (q = 0.016), where alloxan and ketamine each increased activity compared with controls whereas their combination did not. Before correction, ketamine was also associated with higher complex II activity in the hippocampus (p = 0.006) and interactions were detected for complex II-III (p = 0.046) and complex IV (p = 0.019) in the hippocampus and for complex I in the striatum (p = 0.031); these uncorrected findings should be regarded as exploratory. No significant effect of alloxan, ketamine or their interaction was detected for any enzyme in the frontal cortex. In this exploratory study, alloxan-induced diabetes and ketamine were associated with region- and enzyme-specific differences in respiratory chain enzyme activity in the hippocampus and striatum, with alloxan attenuating some ketamine-associated increases. These findings require replication in adequately powered studies including both sexes and complementary measures of mitochondrial function.

Comparable studies

Other preclinical and animal studies on ketamine, most cited first.

Explore topics